Molybdenum is a transition metal that is the essential cofactor of the xanthine oxidase (XO) and xanthine dehydrogenase (XDH) enzymes — the enzymes that are essential for the final steps of purine metabolism, catalyzing the oxidation of hypoxanthine to xanthine and of xanthine to uric acid. Molybdenum is also the cofactor of the aldehyde oxidase (AO) enzyme, which is involved in the metabolism of the aldehydes that are generated by the detoxification reactions of the cytochrome P450 system, and of the sulfite oxidase (SO) enzyme, which is essential for the metabolism of the sulfur-containing amino acids cysteine and methionine. This broad range of molybdenum-dependent enzymes makes molybdenum critical for purine metabolism, for aldehyde detoxification, and for sulfur amino acid metabolism, and its deficiency is associated with a correspondingly broad range of clinical manifestations including severe neurological dysfunction, developmental delay, and the accumulation of the toxic metabolites that result from impaired purine and sulfur amino acid metabolism.
Xanthine Oxidase and Uric Acid
Xanthine oxidase (XO) and xanthine dehydrogenase (XDH) are the enzymes that catalyse the final steps of purine metabolism — the oxidation of hypoxanthine to xanthine and of xanthine to uric acid. The uric acid that is generated by XO/XDH is the final metabolite of purine metabolism in humans (who lack the uricase enzyme that degrades uric acid to allantoin in other mammals), and it is excreted in the urine. The plasma uric acid concentration is determined by the balance between the rate of purine degradation (which generates uric acid) and the rate of uric acid excretion (which is primarily renal, and which is regulated by the urate transporters of the renal tubule). Elevated plasma uric acid (hyperuricemia) is associated with gout (the precipitation of monosodium urate crystals in joints and soft tissues, which produces the acute inflammatory arthritis that is the hallmark of gout), with the metabolic syndrome, with hypertension, and with cardiovascular disease. The XO enzyme is also a significant source of reactive oxygen species (ROS) in the body — it generates superoxide radicals during the oxidation of hypoxanthine and xanthine, and this XO-derived ROS contributes to the oxidative stress that is associated with inflammation, with ischaemia-reperfusion injury, and with the endothelial dysfunction that underlies atherosclerosis.
The clinical importance of molybdenum for XO activity is underscored by the effect of molybdenum deficiency on purine metabolism and on neurological function. Molybdenum deficiency is rare in humans, but when it occurs (as in the rare genetic deficiency of the molybdenum cofactor or as in the dietary molybdenum deficiency that has been documented in some populations with low-molybdenum soils), it produces a clinical syndrome that includes severe neurological dysfunction (including intractable seizures, developmental delay, and the progressive neurodegeneration that characterises the molybdenum cofactor deficiency), elevated xanthine and hypoxanthine in the urine (because XO activity is impaired), and the impaired sulfate metabolism that is the hallmark of sulfite oxidase deficiency (which is also a molybdenum-dependent enzyme and which shares the same molybdenum cofactor). The molybdenum cofactor deficiency is a medical emergency that presents in the neonatal period with intractable seizures and with the rapid progression to severe developmental delay and death if untreated.
Molybdenum and Sulfite Oxidase
Sulfite oxidase (SO) is the molybdenum-dependent enzyme that is essential for the metabolism of the sulfur-containing amino acids cysteine and methionine. Sulfite oxidase catalyses the oxidation of sulfite (SO3 2-) to sulfate (SO4 2-), and without adequate sulfite oxidase activity, the sulfite that is generated by the metabolism of cysteine and methionine accumulates to toxic levels. Sulfite is a potent neurotoxin — it inhibits the glutamine synthetase enzyme in astrocytes, disrupts the glutamate-glutamine cycle, and produces the glutamate-mediated excitotoxicity that is the primary mechanism of the neurological damage in sulfite oxidase deficiency. The clinical manifestations of sulfite oxidase deficiency include severe intellectual disability, intractable seizures, optic atrophy, and the characteristic biochemical markers of impaired sulfate excretion and elevated sulfite in the urine. The treatment of sulfite oxidase deficiency involves dietary cysteine and methionine restriction (to reduce the production of sulfite), and the supplementation with molybdenum (to restore the molybdenum cofactor that is required for SO activity).
Practical Application
For general molybdenum supplementation, the evidence-based dose is 100-200mcg of molybdenum daily (as molybdenum citrate or molybdenum picolinate, the commonly used supplemental forms), which is approximately the RDA of 45mcg daily for adults. Molybdenum is generally well-tolerated with no significant adverse effects at therapeutic doses, though chronic supplementation above 2,000mcg daily should be avoided because molybdenum can accumulate to toxic levels in the body (producing the gout-like symptoms that are associated with hypermolybdenosis and the neurological symptoms that result from the disruption of the sulfur metabolism). For comprehensive purine and sulfur metabolism support, molybdenum pairs well with the low-purine diet (which reduces the production of uric acid and lowers the risk of gout), with the omega-3 fatty acids (which have anti-inflammatory effects that reduce the joint inflammation that is associated with gout), with the antioxidants (including vitamin C and the polyphenols, which reduce the oxidative stress that is associated with hyperuricemia and with the XO-derived ROS production), and with the B-complex vitamins (which are required for the function of many of the enzymes of purine and sulfur amino acid metabolism).
A quality supplement routine can make a real difference to your results.
Leave a Reply